Compare ERII & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERII | TECX |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 554.1M |
| IPO Year | 2008 | N/A |
| Metric | ERII | TECX |
|---|---|---|
| Price | $9.39 | $27.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.07 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 721.9K | 173.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,987,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.55 | N/A |
| P/E Ratio | $27.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.35 | $14.39 |
| 52 Week High | $18.31 | $35.99 |
| Indicator | ERII | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 40.65 |
| Support Level | N/A | $17.71 |
| Resistance Level | $11.54 | $31.88 |
| Average True Range (ATR) | 0.49 | 1.60 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 3.51 | 16.80 |
Energy Recovery Inc designs and manufactures energy-saving technologies. The firm uses its proprietary pressure exchanger technology to help customers in multiple industries improve their operations and lower their emissions. Using its proprietary technology, it offers energy recovery devices, including pressure exchangers, pumps, and turbochargers, mainly used for seawater desalination and wastewater treatment. Additionally, the company is involved in the development of emerging technologies, such as the PX G1300 used in industrial and commercial refrigeration applications. The firm's reportable operating segments are: Water, which generates maximum revenue, and Emerging Technologies. Geographically, it generates maximum revenue from the Middle East, and the rest from other markets.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.